Abstract
Background and Purpose
Although many stroke centers in United States are using intravenous (IV) tenecteplase
(TNK) for acute ischemic stroke patients, there is paucity of comparative data between
IV TNK and IV alteplase from real-world settings.
Materials and Methods
We analyzed the data from 122 healthcare facilities in Cerner Real World Data and
included patients admitted between February 2016 to April 2022 to determine the effect
of IV TNK (compared with IV alteplase) on occurrence of two outcomes in acute ischemic
stroke patients stratified by use of thrombectomy: non-routine discharge or death,
and intracranial hemorrhage after adjusting for potential confounders.
Results
Among 30,643 acute ischemic stroke patients analyzed, 29,480 (96.2%) and 1,163 (3.8%)
patients received IV alteplase and IV TNK, respectively. The proportion of patients
who received thrombectomy was significantly higher among patients who received IV
TNK compared with those who received IV alteplase (16.7% versus 11.0%, p<0.001). Occurrence
of intracranial hemorrhage was more common among patients treated with IV TNK in acute
ischemic stroke patients who did not receive thrombectomy (7.9% versus 5.1%, p<0.001)
but not in those who received thrombectomy (20.1% versus 16.8%, p = 0.234). In the logistic regression analysis, patients treated with IV TNK who did
not receive thrombectomy were at higher risk of intracranial hemorrhage (OR, 1.34,
95% CI 1.05-1.72, p = 0.02) after adjusting for age (age strata), gender, race/ethnicity, hypertension,
diabetes mellitus, atrial fibrillation, hyperlipidemia, malignancy, nicotine dependence,
previous ischemic stroke, previous transient ischemic attack, previous intracerebral
hemorrhage, previous subarachnoid hemorrhage, previous acute myocardial infarction,
atherosclerosis of aorta, previous AKI, congestive heart failure, peripheral vascular
disease, and hospital type, aphasia, hemiplegia, neglect, somnolence, stupor and coma,
dysphagia, and homonymous hemianopsia. There was no difference in the rate of non-routine
discharge or death between patients treated with IV TNK and those treated with IV
alteplase in the multivariate analyses.
Conclusions
In an analysis of real-world data, IV TNK was associated with higher rates of intracranial
hemorrhage compared with IV alteplase in patients with acute ischemic stroke who did
not undergo thrombectomy.
Key Words
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Journal of Stroke and Cerebrovascular DiseasesAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Pharmacokinetics and pharmacodynamics of tenecteplase in fibrinolytic therapy of acute myocardial infarction.Clin Pharmacokinet. 2002; 41 (Epub 2002/11/28PubMed PMID: 12452736): 1229-1245https://doi.org/10.2165/00003088-200241150-00001
- Evidence that tenecteplase is noninferior to alteplase for acute ischemic stroke: meta-analysis of 5 randomized trials.Stroke. 2019; 50 (Epub 2019/07/19PubMed PMID: 31318627): 2156-2162https://doi.org/10.1161/STROKEAHA.119.025080
- Tenecteplase versus alteplase before thrombectomy for ischemic stroke.N Engl J Med. 2018; 378 (Epub 2018/04/26PubMed PMID: 29694815): 1573-1582https://doi.org/10.1056/NEJMoa1716405
- Guidelines for the early management of patients with acute ischemic stroke: 2019 update to the 2018 guidelines for the early management of acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association.Stroke. 2019; 50: e344-e418https://doi.org/10.1161/STR.0000000000000211
- The multiarm optimization of stroke thrombolysis phase 3 acute stroke randomized clinical trial: Rationale and methods.Int J Stroke. 2021; 16 (Epub 2020/12/11PubMed PMID: 33297893): 873-880https://doi.org/10.1177/1747493020978345
- Tenecteplase thrombolysis for acute ischemic stroke.Stroke. 2020; 51: 440-3451
- Should Tenecteplase be given in clinical practice for acute ischemic stroke thrombolysis?.Stroke. 2021; 52: 3075-3080
- Off-label use of tenecteplase for the treatment of acute ischemic stroke: a systematic review and meta-analysis.JAMA Netw Open. 2022; 5 (PMID: 35357458)e224506https://doi.org/10.1001/jamanetworkopen.2022.4506
- Facilitating the study of relationships between COVID-19 and cardiovascular health outcomes using cerner Real-World COVID-19 deidentified dataset.HealthCare Res J. 2020; 1: 17-28
- Acute ischemic stroke and COVID-19: an analysis of 27,676 patients.Stroke. 2021; 52 (Epub 2021 Feb 4. PMID: 33535779; PMCID: PMC7903982): 905-912https://doi.org/10.1161/STROKEAHA.120.031786
- Utilization and outcomes of acute revascularization treatments in ischemic stroke patients with SARS-CoV-2 infection.J Stroke Cerebrovasc Dis. 2022; 31 (PMID: 34689049; PMCID: PMC8498748)106157https://doi.org/10.1016/j.jstrokecerebrovasdis.2021.106157
- Decreased mortality rate among COVID-19 patients prescribed statins: data from electronic health records in the US.Front Med. 2021; 8 (Published 2021 Feb 3)639804https://doi.org/10.3389/fmed.2021.639804
- Discharge destination as a surrogate for Modified Rankin Scale defined outcomes at 3- and 12-months poststroke among stroke survivors.Arch Phys Med Rehabil. 2012; 93 (e1401): 1408-1413
- Results of a prospective observational cohort study of tenecteplase as standard of care stroke thrombolytic.Stroke. 2021; 52 (AP2–AP2)
- Routine use of tenecteplase for thrombolysis in acute ischemic stroke.Stroke. 2021; 52: 1087-1090https://doi.org/10.1161/STROKEAHA.120.030859
- Should tenecteplase replace alteplase for acute thrombolysis?.Stroke. 2021; 52: 1091-1093
- Mechanical thrombectomy in acute ischemic stroke patients performed within and outside clinical trials in the United States.Neurosurgery. 2020; 86 (PMID: 31670379): E2-E8https://doi.org/10.1093/neuros/nyz359
- Race-ethnic disparities in hospital arrival time after ischemic stroke.Ethn Dis. 2017; 27: 125-132https://doi.org/10.18865/ed.27.2.125
- Sex and racial disparity in utilization and outcomes of t-PA and thrombectomy in acute ischemic stroke.J Stroke Cerebrovasc Dis. 2020; 29 (Epub 2020 Jun 30. PMID: 32807414)104954https://doi.org/10.1016/j.jstrokecerebrovasdis.2020.104954
- Real-world treatment trends in endovascular stroke therapy.Stroke. 2019; 50: 683-689
- Validation of acute ischemic stroke codes using the international classification of diseases tenth revision.Am J Cardiol. 2020; 125: 1135
- Strategy for reliable identification of ischaemic stroke, thrombolytics and thrombectomy in large administrative databases.Stroke Vasc Neurol. 2020;
- National trends in utilization and outcomes of endovascular treatment of acute ischemic stroke patients in the mechanical thrombectomy era.Stroke. 2012; 43: 3012-3017
Article info
Publication history
Published online: December 06, 2022
Accepted:
November 10,
2022
Received in revised form:
October 20,
2022
Received:
July 26,
2022
Identification
DOI: https://doi.org/10.1016/j.jstrokecerebrovasdis.2022.106898
Copyright
© 2022 Elsevier Inc. All rights reserved.
